Response to sorafenib in a patient with metastatic Xp11 translocation renal cell carcinoma

Clinical Drug Investigation

Volumn 30, Issue 11, 2010, Pages 799-804

  Hou, Ming Mo ^a   Hsieh, Jia Juan ^b   Chang, Nai Jen ^a   Huang, Hsuan Ying ^a   Wang, Hung Ming ^a   Chuang, Cheng Keng ^a   Hsu, Todd ^b   Chang, John Wen Cheng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

Author keywords

angiogenesis inhibitors; renal cell carcinoma; sorafenib; therapeutic use; treatment

Indexed keywords

SORAFENIB;

ADULT; ANEMIA; ARTICLE; CARCINOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DERMATITIS; HUMAN; KIDNEY CARCINOMA; KIDNEY MASS; KIDNEY NECROSIS; MALE; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGRESSION ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; XP11 TRANSLOCATION CARCINOMA;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, X; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; PLEURAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956474541     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11537220-000000000-00000     Document Type: Article

References (24)

1. Desangles F, Camparo P, Fouet C, et al. Translocation (X;1) associated with a nonpapillary carcinoma in a young woman: a new definition for an Xp11.2 RCC subtype. Cancer Genet Cytogenet 1999; 113: 141-4
2. Perot C, Boccon-Gibod L, Bouvier R, et al. Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study. Cancer Genet Cytogenet 2003; 143: 93-9
3. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 2005; 25: 363-78
4. Bruder E, Passera O, Harms D, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004; 28: 1117-32
5. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001; 159: 179-92
6. Argani P, Ladanyi M. Renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions, pages 37-38. In: Eble JN, Sauter G, Epstein JI, et al. editors. World Health Organization classification of tumours: tumours of the urinary system and male genital organs. Lyon: International Agency for Reseach on Cancer, 2004
7. Meyer PN, Clark JI, Flanigan RC, et al. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol 2007; 128: 70-9
8. Chang IW, Huang HY, Sung MT. Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts. Am J Surg Pathol 2009; 33: 1894-901
9. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96
10. Argani P, Antonescu CR, Couturier J, et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol 2002; 26: 1553-66
11. Argani P, Lui MY, Couturier J, et al. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 2003; 22: 5374-8
12. Clark J, Lu YJ, Sidhar SK, et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 1997; 15: 2233-9
13. Weterman MA, Wilbrink M, Geurts van Kessel A. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc Natl Acad Sci U S A 1996; 93: 15294-8
14. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais dImmunotherapie. N Engl J Med 1998; 338: 1272-8
15. Ritchie AWS. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353: 14-7
16. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34
17. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24
18. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34
19. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81
20. Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002; 417: 975-8
21. Pwint TP, Macaulay V, Roberts IS, et al. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol. Epub 2009 Dec 3
22. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007; 67: 919-29
23. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109
24. Steingrimsson E, Tessarollo L, Reid SW, et al. The bHLHZip transcription factor Tfeb is essential for placental vascularization. Development 1998; 125: 4607-16